Die systemischen Vaskulitiden

Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37(2):187–92. Jennette JC, Falk RJ, Bacon PA. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. 2012. Holl-Ulrich K. Vaskulitis Neue Nomenklatur der Chapel-Hill-Konferenz 2012. Z Rheumatol. 2014;73:823–35. Weigand S, Fleck M. Großgefäßvaskulitis. Z Rheumatol. 2014;73:447–57. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61(10):1454–61. Schirmer M, Dejaco C, Schmidt WA. Riesenzellarteriitis Update: Diagnose und Therapie. Z Rheumatol. 2012;71:754–9. Chew S, Kerr NM, Danesh-Meyer HV. Giant cell arteritis. J Clin Neurosci. 2009;16(10):1263–8. Puchner R. Riesenzellarteriitis. In: Puchner R (Hrsg.). Rheumatologie aus der Praxis. Wien: Springer; 2012. S. 146–8. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68(3):318–23. Elefante E, Tripoli A, Ferro F, Baldini C. One year in review: systemic vaskulitis. Clin Exp Rheumatol. 2016;34(Suppl 97):S1–S6. Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56(8):2789–97. Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken). 2012;64(11):1720–9. Loricera J, Blanco R, Hernandez JL, et al. Tocilizumab in giant cell arteritis: multicenter open-label study of 22 patients. Semin Arthritis Rheum. 2015;44:717–23. Hafner F. Vaskulitiden großer Gefäße. Wien Klin Wochenschr Educ. 2014;9:15–32. Keser G, Ditreskeneli H, Aksu K. Management of Takayasu vaskulitis. A systematic review. Rheumatology (Oxford). 2014;53(5):793–801. Loricera J, Blanco R, Hernández JL, et al. Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clin Exp Rheumatol. 2016;34(3 Suppl 97):44–53. Nakaoka Y, Higuchi K, Arita Y, et al. Tocilizumab for the treatment of patients with refractory Takayasu arteritis. Int Heart J. 2013;54(6):405–11. Kussmaul A, Maier R. Über eine bisher nicht beschriebene eigenthümliche Arterienerkrankung (Periarteriitis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellähmung einhergeht. Dtsch Arch Klin Med. 1866;1:484. Guillevin L, Mahr A, Callard P, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore). 2005;84:313–22. Schirmer JH, Holl-Ulrich K, Moosig F. Polyarteriitis nodosa Differentialdiagnose und Therapie. Z Rheumatol. 2014;73:917–27. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum. 2005;53:93–9. Pagnoux C, Seror R, Henegar C, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum. 2010;62:616–26. Henegar C, Pagnoux C, Puéchal X, et al. A paradigm of diagnostic criteria for polyarteritis nodosa: analysis of a series of 949 patients with vasculitides. Arthritis Rheum. 2008;58:1528–38. De Menthon M, Mahr A. Treating polyarteriitis nodosa: current state of the art. Clin Exp Rheumatol. 2011;29:S110–S116. De Virgilio A, Greco A, Magliulo G, et al. Polyarteritis nodosa: a contemporary overview. Autoimmun Rev. 2016;15:564–70. Newburger JW, Takahashi M, Gerber M. Diagnosis, treatment and long term management of Kawasaki disease. Circulation. 2004;110:2747–71. Neudorf U. Kawasaki Syndrom. In: Hettenkofer H‑J, Schneider M, Braun J (Hrsg.). Rheumatologie Diagnostik – Klinik – Therapie. Stuttgart: Thieme; 2014. S. 279–82. Holle JU. ANCA („anti-neutrophil cytoplasm antibody“)-assoziierte Vaskulitiden. Z Rheumatol. 2013;72:445–56. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 1990;33:1101–7. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094–100. Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66:605–17. Wegener F. Über eine eigenartige rhinogene Granulomatose mit besonderer Beteiligung des Arteriensystems und der Nieren. Beitr Pathol Anat. 1939;102:36–68. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, et al. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis registry. Arthritis Rheum. 2005;53:93–9. Catanaso M, Macchioni P, Boiardi L, et al. Epidemiology of granulomatosis with poyangiitis (Wegener’s Granulomatosis) in northern Italy: a 15-year population based study. Semin Arthritis Rheum. 2014;44:202–7. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68:310–7. Holle JU, Gross WL, Holl-Ulrich K, et al. Prospective long-term follow-up of patients with localised Wegener’s granulomatosis: Does it occur as persistent disease stage? Ann Rheum Dis. 2010;69:1934–9. Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42:421–30. Holle JU, Gross WL, Latza U, et al. Improved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 2011;63:257–66. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221–32. Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180–8. Vaglio A, Moosig F, Zwerina J. Churg-Strauss syndrome: update on pathophysiology and treatment. Curr Opin Rheumatol. 2012;24:24–30. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996;75(1):17–28. doi:10.1097/00005792-199601000-00003. Ribi C, Cohen P, Mahr A, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized open-label study of seventy-two patients. Arthritis Rheum. 2008;58:586–94. Cohen P, Pagnoux C, Mahr A, et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cycloposphamide pulses in forty-eight patients. Arthritis Rheum. 2007;57:676–93. Little MA, Nightingale P, Verburgh CA, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2012;69:1036–43. Hirayama K, Yamagata K, Kobayashi M, Koyama A. Anti-glomerular basement membrane antibody disease in Japan: part of the nationwide rapidly progressive glomerulonephritis survey in Japan. Clin Exp Nephrol. 2008;12(5):339–47. Zhao C, Zhao J, Xiao-yu J, et al. Anti-glomerular basement membrane disease outcomes of different therapeutic regimens in a large single-center chinese cohort study. Medicine (Baltimore). 2011;90:303–11. Hellmark T, Segelmark M. Diagnosis and classification of Goodpasture’s disease (anti-GBM). J Autoimmun. 2014;48–49:108–12. doi:10.1016/j.jaut.2014.01.024. Touzot M, Poisson J, Faguer S. Rituximab in anti-GMB disease: a retrospective study of 8 patients. J Autoimmun. 2015;60:74–9. Blank N, Lorenz HM. Kryoglobulinämische Vaskulitiden. Z Rheumatol. 2016;75:303–15. Brouet JC, Clauvel JP, Danon F, et al. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med. 1974;57(5):775–88. Cacoub P, Comarmond C, Domont F, et al. Cryoglobulinemia Vasculitis. Am J Med. 2015;128(9):950–5. Terrier B, Cacoub P. Cryoglobulinemia vasculitis: an update. Curr Opin Rheumatol. 2013;25(1):10–8. Sarrazin C, Berg T, Buggisch P, et al. Aktuelle Empfehlung zur Therapie der chronischen Hepatitis C. S3 guideline hepatitis C addendum. Z Gastroenterol. 2015;53:320–34. Terrier B, Carrat F, Krastinova E, et al. Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey. Ann Rheum Dis. 2013;72(3):374–80. Hospach T, Huppertz HI. Purpura Schönlein Henoch-Häufigste Vaskulitis des Kinder und Jugendalters. Z Rheumatol. 2011;70:829–37. Klass MM. IgA-Vaskulitis (Purpura Schönlein Henoch). In: Hettenkofer H‑J, Schneider M, Braun J (Hrsg.). Rheumatologie Diagnostik – Klinik – Therapie. Stuttgart: Thieme; 2014. S. 269–70. Grotz W, Baba HA, Becker JU, Baumgärtel MW. Hypokomplementämisches Urtikaria-Vaskulitis-Syndrom. Dtsch Arztebl. 2009;106(46):756–63. Chehab G. Cogan-Syndrom. In: Hettenkofer H‑J, Schneider M, Braun J (Hrsg.). Rheumatologie Diagnostik – Klinik – Therapie. Stuttgart: Thieme; 2014. S. 297–8. Kötter I, Xenitidis T, Fierlbeck G, et al. Morbus Behçet. Z Rheumatol. 2012;71:685–97. Anonymous. Criteria for diagnosis of Behcet’s disease. International Study Group for Behçet’s Disease. Lancet. 1990;335:1078–80. Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behçet’s syndrome – a phase 2, placebo-controlled study. N Engl J Med. 2015;372:1510–8. Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656–62. Lie JT. Systemic and isolated vasculitis: a rational approach to classification and pathologic diagnosis. Pathol Annu. 1989;24(Pt 1):25–114.